Mas/MrgD Agonist Program

About Xitra Therapeutics

Xitra Therapeutics, founded in 2018 and based in Munich, is a private, pre-clinical stage biotech developing oral small molecule agonists of the Mas and MrgD receptors. The company's platform aims to harness the protective angiotensin-(1-7) pathway for treating severe pediatric and inflammatory conditions, offering a potential advantage over peptide-based therapies. As a subsidiary of Constant Therapeutics, Xitra has secured non-dilutive grant funding and is led by an experienced scientific founder. The company represents a focused effort to address high-unmet-need rare diseases with a novel pharmacological approach.

About Xitra Therapeutics

Xitra Therapeutics, founded in 2018 and based in Munich, is a private, pre-clinical stage biotech developing oral small molecule agonists of the Mas and MrgD receptors. The company's platform aims to harness the protective angiotensin-(1-7) pathway for treating severe pediatric and inflammatory conditions, offering a potential advantage over peptide-based therapies. As a subsidiary of Constant Therapeutics, Xitra has secured non-dilutive grant funding and is led by an experienced scientific founder. The company represents a focused effort to address high-unmet-need rare diseases with a novel pharmacological approach.

Therapeutic Areas